Last reviewed:
Many people reach an undetectable viral load within weeks to a few months after starting effective ART; CDC says most get HIV under control within six months. The timing varies. NIH describes suppression generally within 8–12 weeks when medicines are taken consistently and the virus is susceptible. Follow-up blood tests, rather than elapsed time alone, show how your treatment is working.[1][2][10]
The timeline you can expect
HIV.gov states that almost everyone who takes HIV medicine as prescribed can reach an undetectable viral load, usually within six months after starting treatment.[1] CDC frames the same interval as most people getting HIV under control within six months.[2]
Six months is a broad public-health estimate, not a deadline or a reason to ignore an unexpected result. NIH says people taking an effective regimen consistently, without resistance to its drugs, generally achieve suppression within 8–12 weeks; some take longer. Your care team should check the trend well before six months.[10][3]
NIH recommends bictegravir/TAF/FTC or a dolutegravir-based regimen for many people starting ART. Dolutegravir/lamivudine is a two-drug option only in suitable circumstances; it is not an integrase inhibitor plus two nucleoside analogues. Previous injectable cabotegravir PrEP, hepatitis B, resistance and other factors can change the choice.[4]
Starting sooner shortens the whole clock. The guidelines recommend initiating treatment immediately or as soon as possible after diagnosis specifically to decrease the time to viral suppression.[5]
"Suppressed" and "undetectable" are not the same word
For sexual U=U, the evidence-based threshold is sustained HIV RNA below 200 copies/mL, including detectable results below that level. For treatment monitoring, the goal is generally a result below the assay’s detection limit. “Suppression” therefore needs context rather than one universal definition.[11][6]
Undetectable is relative to your test. HIV.gov describes it as a level so low a standard lab test cannot detect it, usually defined as fewer than 20 copies per milliliter depending on which assay is used.[1] NIH's glossary defines it simply as when the amount of HIV in the blood is too low to be detected with a viral load test.[7]
Keeping suppression over time matters more than a single result. NIH’s criteria for switching to long-acting cabotegravir/rilpivirine generally include at least three months of suppression below 50 copies/mL, suitable resistance history and other clinical requirements. That switch criterion is different from advice about sexual prevention when first starting ART.[12][7][2]
What moves your timeline
Starting viral load can affect the time needed to reach a low result. Other factors include how consistently medication can be taken, the regimen’s activity, drug interactions and resistance. There is no reliable universal ranking of these factors for every person.[10]
Taking ART as prescribed helps both reach and maintain suppression. Ask for support if cost, side effects, housing, stigma or another barrier makes that difficult. In HPTN 052, linked transmissions occurred before suppression or after treatment failure; maintaining effective treatment matters.[6]
Baseline resistance testing helps choose treatment, but ART can usually start before results return. After previous long-acting cabotegravir PrEP, an integrase-based starting regimen should wait for an appropriate genotype showing no integrase resistance; NIH provides a boosted-darunavir alternative while results are pending. Tell the clinician about any past PrEP.[5][4]
If viral load is not falling as expected, contact the care team. They may repeat the test and assess medication access, adherence, interactions, tolerability and resistance before choosing next steps. Do not stop or change treatment on your own; the best plan depends on the results.[13]
Florida angle: rapid-start treatment goals
Florida’s October 2023 Test and Treat guidance aims for ART within 24 hours when possible, or within 72 hours, and calls for rapid provider visits and medication access. Broward describes immediate linkage through its program. These are service goals, not a guarantee that every site can start everyone the same day; clinical exceptions can affect ART timing.[5][8][9]
Related questions
Can I become undetectable in four weeks?
It is possible, but a one-month result is not guaranteed. NIH generally expects suppression within 8–12 weeks when the regimen is active and taken consistently, with some people taking longer. Early repeat testing helps your clinician judge whether the decline is appropriate.[10]
What if I am still detectable at six months?
Do I need to be undetectable before sex is safe?
Maintaining HIV RNA below 200 copies/mL on ART prevents sexual HIV transmission. When starting treatment, NIH recommends another prevention method for at least the first six months and until suppression below 200 is documented. This does not mean waiting six more months after the first suppressed test. Discuss follow-up and any higher results with the care team.[11]
How often will my viral load be checked?
NIH recommends viral load at ART initiation and again within 4–8 weeks, repeating every 4–8 weeks until below the assay’s detection limit. Stable suppression is generally monitored every 3–4 months; selected people with more than a year of suppression and stable health may extend to six months. Pregnancy or clinical concerns can require closer checks.[10]
Related from RiseUpToHIV
References & Sources
- HIV.gov — Viral Suppression and an Undetectable Viral Load. States almost everyone reaches undetectable usually within six months, defines suppression as under 200 copies/mL and undetectable as usually under 20 copies/mL. ↩ ↩ ↩
- CDC — Treating HIV. States most people can get HIV under control within six months and that injectable treatment requires at least three months of suppression. ↩ ↩ ↩
- HIV.gov — HIV Treatment as Prevention. States many people reach undetectable very quickly while a small portion take longer. ↩
- NIH DHHS Clinical Guidelines — What to Start. Lists recommended second-generation integrase inhibitor-based initial regimens and integrase resistance testing after cabotegravir PrEP exposure. ↩ ↩
- NIH DHHS Clinical Guidelines — Initiation of Antiretroviral Therapy. Recommends immediate ART to decrease time to viral suppression and baseline genotypic resistance testing without delaying treatment. ↩ ↩ ↩
- CDC — HIV Treatment as Prevention. Defines viral suppression as under 200 copies/mL and describes when linked transmissions occurred in HPTN 052. ↩ ↩
- NIH Clinicalinfo — Undetectable Viral Load: a level too low for the viral-load test to detect. Source. ↩↩
- Florida DOH — Test and Treat and Re-Engage in Care Guidance, October 2023: rapid-start goals and service procedures. Source. ↩
- Florida Department of Health in Broward County — Test and Treat. Describes immediate linkage to HIV primary care and ART initiation at the time of diagnosis. ↩
- NIH/DHHS (September 25, 2025) — Viral-load/CD4 monitoring: expected response, repeat tests and monitoring intervals. Source. Checked September 21, 2026. ↩ ↩ ↩ ↩ ↩ ↩
- NIH/DHHS — Sexual U=U threshold and prevention during the first six months of ART. Source. Checked September 21, 2026. ↩ ↩
- NIH/DHHS — Optimizing ART: long-acting cabotegravir/rilpivirine switch criteria. Source. Checked September 21, 2026. ↩
- NIH/DHHS — Virologic failure: low-level viremia, repeat testing and individualized assessment. Source. Checked September 21, 2026. ↩ ↩
Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.